BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       


HIV/AIDS and Related Conditions: Selected Epidemiologic and Cost Facts

A recent report from the Pharmaceutical Research and Manufacturers of America (PhRMA; Washington, DC) lists drugs and vaccines in clinical development for HIV/AIDS and related conditions and also details related epidemiologic and cost facts. According to the PhRMA report, the global AIDS pandemic has killed 28 million people and infected an estimated 42 million people worldwide, about 67% from sub-Saharan Africa and 20% from Asia and the Pacific. It is estimated that 45 million new cases of HIV infection may occur by 2010 unless a dramatic breakthrough is achieved with an HIV vaccine. In the U.S., it is estimated that as many as 950,000 individuals are living with HIV infection, and they are living longer because of treatment with new drugs, which have helped to substantially reduce the U.S. death rate from AIDS in recent years. In the U.S.:

  • 82 drugs are approved for the treatment of HIV/AIDS and related conditions;
  • 79 drugs for the treatment of HIV/AIDS and related conditions are in clinical trials; and
  • 16 vaccines are in clinical development for prevention of HIV infection and, hopefully, control of the global AIDS pandemic.

The following table lists selected epidemiologic and cost facts about HIV/AIDS and related conditions.

Selected Facts about HIV/AIDS
Parameter Estimate Estimate
UNITED STATES
  U.S. AIDS cases (through Dec 2002)1 U.S. AIDS deaths (through Dec 2002)1
Adults/Adolescents 849,780 496,598
Pediatric (under age 13) 9,074 5,071
Total 858,854 501,669
 
Living with HIV 850,000-950,000 1/4 are unaware of their infection2
New HIV infections per year 40,000 (1/2 younger than 25; 70% male)2  
New diagnoses of HIV/AIDS increased (after decreasing since the mid-1990s, diagnoses increased in 2002) 3.2% increase from 2001 (25,643) to 2002 (26,464); 71% were men1  
Percent of progression from HIV to AIDS within 12 months after HIV diagnosis 39%1  
Estimated number of deaths among people with AIDS Declined 14% from 1998 (19,005) to 2002 (16,371)1  
Health insurance 1/3 have private insurance, 1/5 is uninsured, Medicare-Medicaid cover the remaining 1/23  
HIV transmission from mother to child during pregnancy, labor, and delivery or by breast-feeding Accounts for 91% of cases in children; Between1992 and 2002, perinatally acquired AIDS cases declined 90%, from 912 to 90 cases per year  
WORLDWIDE
Living with HIV (end of 2003) 35.7 million adults; Almost 50% are women 2.1 million children
New HIV infections (2003) 4.8 million (14,000/day) More than 95% are in developing countries
HIV/AIDS-associated illness-caused deaths (2003) 2.9 million 490,000 children younger than age 15
OPPORTUNISTIC INFECTIONS
Opportunistic fungal infections in AIDS Rates range from 60%-90% for mucosal candidiasis to 6%-30% for invasive mycoses (cryptococcosis, histoplasmosis, coccidioimycosis)2  
Esophageal candidiasis Most common opportunistic infection in developed countries; Affects up to 20% of AIDS patients4  
Cryptococcosis Worldwide ranks 2nd or 3rd2  
Cytomegalovirus (CMV) Reduced in HIV patients by 75% by combination antiviral therapy but still affects 5% of people with HIV5  
Hepatitis B virus (HBV) CDC: 1.25 million Americans are chronically infected; 100,000 new infections in 20046 100 times more infectious than AIDS
HBV About half of new cases caused by sexual intercourse; In 1995, about 1 in 3 with acute HBV infection had a history of another STD1 Up to 6,000 people die of HBV-related liver complications each year
Hepatitis C virus (HCV) The most common chronic blood borne infection in the U.S.; An estimated 4 million people have been infected with HCV7 Up to 85% of people infected with HCV each year will develop chronic infection
HCV + HIV Up to 1/4 of HIV-positive individuals in the U.S. are co-infected with HCV In 1999, the CDC added HCV to the list of opportunistic infections associated with HIV
HCV-related end-stage liver disease + HIV Since 2000, HCV-related end-stage liver disease has been recognized as a leading cause of death among people with HIV8 One study found that >40% of deaths in HIV-positive individuals were associated with liver disease either as a primary or associated cause9
HCV + HIV in pregnancy Transmission of HCV to offspring among mothers with HCV alone is about 2%, but rates 2-3 times higher have been reported among those with both HCV and HIV infection10  
U.S. rates of STDs--including HIV/AIDS, gonorrhea, genital herpes, HPV, and HBV--are, by far, the highest of the industrialized world An estimated 15.3 million new cases of STDs are reported each year in the U.S.1 Health problems caused by STDs tend to be more severe for women than for men
Genital herpes simplex virus (HSV) Affects an estimated 1 out of 4 (45 million) in the U.S. About 500,000 new cases per year1
Sexually transmitted human papillomavirus (HPV) 24 million infected in the U.S.; Health experts estimate that there are more cases of genital HPV infection than of any other STD in the U.S.2 Approximately 5.5 million new cases reported each year
HPV About 2/3 of those who have sexual contact with a partner with genital warts (caused by low-risk types of HPV) usually develop warts themselves within 3 months of contact2  
Kaposi's sarcoma (KS) In the past, about 1 in 4 homosexual or bisexual males with AIDS developed KS11 Because of more effective HIV treatments, the rate of KS among that population has dropped to about 1/7 of its peak
AIDS-related lymphoma (non-Hodgkin's lymphoma or NHL) About 10% of people with HIV may eventually develop NHL (a rate >80 times higher than for the general population)5 Although the rate declined about 40% because of combination antiviral therapy, lymphoma still accounts for the deaths of about 20% of people with HIV
Pneumocystis carinii pneumonia (PCP) The most common opportunistic infection in people with HIV; Without treatment, >85% would eventually develop PCP5 Declining; PCP was the first AIDS-defining diagnosis for only 32% of cases in 1993, compared to 63% in 1987; PCP was the cause of death in 14% of AIDS deaths in 1993, compared to 32% in 1987
COSTS (U.S.)
Average lifetime cost per case of genital herpes $417 for women; $511 for men12 Total direct medical costs in 2000 were $292.7 million
Average lifetime cost per case of HBV infection $77912 Total direct medical costs in 2000 were $5.8 million
Average lifetime cost per case of HPV infection $1,228 for women; $27 for men12 Total direct medical costs in 2000 were $2.9 billion
48-week course of treatment for HCV infection $40,0008  
Lifetime treatment cost for a person with HIV About $155,0001 40,000 infected yearly results in an annualized cost of >$6 billion; During the last 5 years alone, an estimated 200,000 people have been infected with HIV; Treating them over the rest of their lives will cost $31 billion
Mother-to-child HIV transmission Prevention costs about $33,000 per infection averted  
Total direct and indirect costs of the major STDs (including HIV/AIDS, HSV, HPV, and HBV) and complications Estimated to total nearly $17 billion in 19941 Direct costs include expenditures for medical and non-medical services and materials); Indirect costs are mainly lost wages

  1. U.S. Centers for Disease Control and Prevention
  2. National Institute of Allergy and Infectious Diseases
  3. Rand Health
  4. HIV InSite, a project of the University of California/San Francisco
  5. The Body: An AIDS and HIV Information Resource
  6. Hepatitis B Foundation
  7. American Liver Foundation
  8. Treatment Action Group
  9. Reuters Health Information
  10. MedReviews, LLC: OHCV and HIV: A Tale of Two Viruses,O Kenneth E. Sherman, M.D., Ph.D., Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH
  11. American Cancer Society
  12. Focus on the Family

 


Source: Adapted from PhRMA report.

Source: D&MD

To view and purchase D&MD reports click here!  

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.